Anxiety disorders affect roughly 1 in 5 adults, and conventional treatments — SSRIs, benzodiazepines, buspirone — leave many patients inadequately managed due to side effects, tolerance, or partial efficacy. Research peptides offer mechanistically distinct approaches to anxiety that, for some individuals, address what conventional drugs miss. Selank and the DSIP/Semax family have the strongest evidence bases for anxiety and stress-specific applications.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Research peptides for anxiety, stress, and social anxiety — mechanisms, dosing, and how they compare to conventional anxiolytics.
Selank: The Evidence-Based Choice
Selank is registered in Russia as an anxiolytic medication — giving it a rare clinical pedigree among research peptides. Phase II and III clinical trials in Russia demonstrated its efficacy for generalized anxiety disorder and phobic disorders, with response rates comparable to benzodiazepines and a dramatically superior side effect profile. The key clinical advantages: no sedation, no memory impairment, no tolerance development, and no withdrawal syndrome on discontinuation.
Mechanistically, Selank modulates GABA-A receptors (the same target as benzodiazepines) without causing receptor downregulation. It also stabilises enkephalins and modestly upregulates BDNF, contributing to improved mood resilience rather than simple symptom suppression. For individuals seeking benzodiazepine-like anxiety relief without addiction risk, Selank is the most evidence-supported option in this category.
BPC-157: Addressing the Dopamine and Stress Axis
BPC-157 has underappreciated relevance for anxiety through its modulation of the dopamine system. Animal studies show BPC-157 protecting against dopaminergic neurotoxicity and normalising dopamine receptor sensitivity — important because dopamine dysregulation is implicated in anxiety, anhedonia, and stress vulnerability. BPC-157 also modulates the HPA (hypothalamic-pituitary-adrenal) axis, the stress hormone system that chronically dysregulates in anxiety disorders.
For anxiety with a strong stress and HPA axis component — chronic stress, burnout, trauma-related anxiety — BPC-157's effects on the dopamine-HPA system provide a mechanism that Selank's GABA modulation does not address. The two are complementary in anxiety with both dopaminergic and GABAergic components.
DSIP: The Stress Peptide
DSIP (Delta Sleep-Inducing Peptide) was originally isolated for its sleep-promoting effects but has subsequently shown significant anxiolytic and stress-normalising properties. It reduces ACTH secretion and normalises aberrant cortisol patterns — directly addressing the elevated cortisol seen in chronic anxiety and stress disorders. DSIP also improves sleep quality, and given the bidirectional relationship between sleep disruption and anxiety, its sleep-normalising effects may account for part of its anxiolytic benefit.
DSIP is less commonly discussed than Selank but represents a distinct approach for anxiety with prominent sleep and cortisol dysregulation — a profile common in generalised anxiety disorder and burnout presentations.
Anxiety Peptide Protocol Guide
| Peptide | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Selank | 250–500 mcg | Intranasal | Once or twice daily; as-needed for acute anxiety | Primary anxiolytic; most evidence |
| NA-Selank | 100–250 mcg | Intranasal | Once or twice daily | More potent acetylated form |
| BPC-157 | 250–500 mcg | SubQ | Once daily | Dopamine/HPA axis support |
| DSIP | 100–300 mcg | SubQ | 3–5x/week, evening | Sleep + cortisol normalisation |
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Selank should not be used to replace benzodiazepines without medical supervision — benzo withdrawal can be medically serious. Selank may be appropriate as a replacement in new anxiety cases that have not yet been started on benzodiazepines, or under physician supervision during a gradual benzo taper. Its comparable efficacy and superior safety profile make it a rational alternative in appropriate clinical contexts.
Acute anxiolytic effects typically appear within 20–40 minutes of intranasal administration. For situational anxiety (public speaking, social events), as-needed dosing 30 minutes before the stressor is practical. For generalised anxiety, consistent daily dosing produces progressive improvement over 1–3 weeks as receptor modulation effects accumulate.
Selank has clinical safety data from its Russian approval process and a long community track record with no documented serious adverse events. BPC-157 and DSIP are less extensively studied. As with any compound, starting with the minimum effective dose, monitoring response carefully, and disclosing use to a treating physician is advisable — particularly for individuals on existing psychiatric medications.
Selank is the most direct choice for social anxiety, reducing the anxious anticipation and in-situation anxiety that characterises the condition without the sedation that makes some anxiolytics counterproductive in social contexts. Community reports frequently highlight social ease as a primary effect. For persistent social anxiety with underlying self-confidence or dopamine system components, BPC-157 as an adjunct may provide additional benefit.
This is potentially the most appropriate use case for BPC-157 alongside Selank. Chronic stress and burnout involve HPA axis dysregulation, dopaminergic blunting, and neuroinflammation — all targets of BPC-157. Selank addresses the anxiety symptoms; BPC-157 addresses some of the underlying neurobiological changes from chronic stress. A combined protocol over 6–8 weeks is a reasonable research approach for this presentation.